TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) is now available.
Shanghai Fosun Pharmaceutical announced that its subsidiary, Suzhou Erye Pharmaceutical Co., Ltd., has had its drug registration application for Heparin Sodium Injection accepted by the National Medical Products Administration. This drug is intended for multiple medical uses, including the prevention and treatment of various thromboembolic conditions, and its acceptance marks a significant step in the company’s expansion of its pharmaceutical offerings, potentially enhancing its competitive position in the market.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company focuses on the development, manufacturing, and distribution of pharmaceutical products, with a market emphasis on innovative drug solutions.
Average Trading Volume: 6,907,858
Technical Sentiment Signal: Buy
Current Market Cap: HK$75.52B
For an in-depth examination of 2196 stock, go to TipRanks’ Overview page.